- HeraMED (HMD) will have its pregnancy monitoring solutions, HeraBEAT and HeraCARE, tested in a pilot study at Israel’s largest hospital, the Sheba Medical Centre
- In the first stage of the pilot, medical staff at Sheba will use the HeraBEAT smart pregnancy monitor in its dedicated pregnancy COVID-19 unit
- The second stage of the pilot will include a much wider study, which will provide additional uses beyond COVID-19
- On market close, HeraMED is in the grey and trading at 10.5 cents per share.
HeraMED (HMD) will have its pregnancy monitoring solutions, HeraBEAT and HeraCARE, tested in a pilot study at Israel’s largest hospital, the Sheba Medical Centre.
Sheba is home to over a quarter of Israel’s medical research and was recently placed ninth in Newsweek’s 2020 hospital rankings.
The pilot will be undertaken in numerous stages. During the first stage, which will begin immediately, Sheba will use the HeraBEAT smart pregnancy monitor in its dedicated pregnancy COVID-19 unit.
Pregnant women who are admitted to the COVID-19 unit require continuous monitoring. The HeraBEAT will help midwives and obstetricians monitor real-time foetal and maternal heart rate monitoring. This method will limit the amount of physical interaction and therefore reducing the risk of COVID-19 exposure.
The second stage of the pilot will include a much wider study, which will provide additional uses beyond COVID-19, such as high-risk pregnancies. This stage has potential to include a wide audience of pregnant women.
Read the article by Lisa Simcock in The Market Herald.